TOBRASONE
LOE Approachingfluorometholone acetate; tobramycin
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jul 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TOBRASONE (fluorometholone acetate; tobramycin) is clinical pharmacology corticosteroids suppress the inflammatory response to inciting agents of mechanical, chemical or immunological nature. First approved in 1989.
Drug data last refreshed 17h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBRASONE is a fixed-combination ophthalmic suspension containing fluorometholone acetate (a corticosteroid) and tobramycin (an aminoglycoside antibiotic) approved in 1989 for topical eye use. It suppresses inflammatory response while providing broad-spectrum antimicrobial coverage for bacterial ocular infections and inflammation. The corticosteroid component works by inhibiting the inflammatory cascade, though the exact mechanism remains incompletely understood.
LOE Approaching
As TOBRASONE approaches loss of exclusivity with competitive pressure at 30%, commercial teams face significant margin compression and portfolio consolidation decisions.
Mechanism of Action
CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to inciting agents of mechanical, chemical or immunological nature. No generally accepted explanation of this steroid property has been advanced. Corticosteroids cause a rise in intraocular pressure (IOP) in susceptible…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TOBRASONE offers limited career growth due to its LOE-approaching lifecycle and minimal linked job openings; opportunities focus on defensive commercial strategies, payer negotiations, and cost-containment execution rather than expansion or innovation. Career trajectories will likely shift to post-LOE portfolio management or lateral moves to growth-stage products within the ophthalmology or broader pharmaceutical portfolio.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.